![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Kyowa Pharma Chemical Co., Ltd. Takaoka Jp, based in Japan, is a pharmaceutical company that stands out with its certifications from FDA.
One of their significant offerings is Dinoprostone, supported by a 'Valid' Certificate of Suitability (CEP) with the number R1-CEP 2003-029 - Rev 02
This Chemical Type CEP, issued on August 09, 2022, remains in force until January 01, 1970, ensuring its reliability within the pharmaceutical industry.
Substance Number 1311 associated with this CEP further emphasizes